TiGenix spins out drug discovery activities into Arcarios
This article was originally published in Scrip
Executive Summary
TiGenix, the Belgium-based biotech, has spun out its drug discovery activities into new company Arcarios, which was also formed with the help of the Catholic University of Leuven (KULeuven), Ghent University (UGent), the Dutch biotech firm Therosteon and a consortium of investors.